Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-22
2008-07-22
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07402564
ABSTRACT:
The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.
REFERENCES:
patent: 5965701 (1999-10-01), Junien et al.
patent: 6191103 (2001-02-01), Shohet et al.
patent: 6780846 (2004-08-01), O'Mahony et al.
patent: 6984719 (2006-01-01), Chemtob et al.
patent: 2005/0113294 (2005-05-01), Dolle
patent: 2006/0229252 (2006-10-01), Falla et al.
patent: 43 10643 (1993-04-01), None
patent: 0 249 169 (1987-06-01), None
patent: 0 334 244 (1989-03-01), None
patent: 0 342 962 (1989-05-01), None
patent: 0 361 977 (1989-09-01), None
patent: 0 505 680 (1992-01-01), None
patent: 0 517 589 (1996-12-01), None
patent: 0 503 301 (1997-11-01), None
patent: WO 94/21242 (1994-09-01), None
patent: WO 95/00546 (1995-01-01), None
patent: WO 95/22557 (1995-08-01), None
patent: WO 96/02267 (1996-01-01), None
patent: WO 97/07130 (1997-02-01), None
patent: WO 97/09995 (1997-03-01), None
patent: WO 98/08492 (1998-03-01), None
patent: WO 98/08868 (1998-03-01), None
patent: WO 99/21877 (1999-05-01), None
patent: WO 99/32510 (1999-07-01), None
patent: WO 2006/058539 (2006-06-01), None
patent: WO 2006/058539 (2006-06-01), None
Vippagunta et al. “Crystalline solids” Adv. Drug Delivery Rev., 2001, 48, 2-26.
Bentley, G.A. et al., Evidence for an action of morphine and the enkephalins on sensory nerve endings in the mouse peritoneum, Br. J. Pharmac., 73:325-332 (1981).
Diop, Laurent et al., Peripheral k-opioid receptors mediate the antinociceptive effect of fetodozine on the duodenal pain reflex in rat, European Journal of Pharmacology 271, pp. 65-71 (1994).
Iyer, S. et al., Characterization and Biological Significance of Immunosuppresive Peptide D2702.75-84 (E→V) Binding Protein, J. Biol. Chem., vol. 273, No. 5, pp. 2692-2697 (1998).
Junien and Riviere, Review article: the hypersensitive gut—peripheral kappa agonists as a new pharmacological approach, Alimentary Pharmacology and Therapeutics, 9:117-126 (1995).
Lamb, J.R. et al., Influence of antigen structure on the activation and induction of unresponsiveness in cloned human T lymphocytes, Immunology, 57, pp. 331-335 (1986).
Ostergaard, S. et al., Novel avidin and streptavidin binding sequences found in synthetic peptide libraries, FEBS Letters, 362, pp. 306-308 (1995).
Riviere, Pierre J.M. et al., Fedotozine Reverses Ileus Induced by Surgery or Peritonitis: Action at Peripheralk-Opioid Receptors, Gastroenterology 104:724-731 (1993).
Schröder, E., Synthese des all-D-Val5-Angiotensin II-Asp1-β-amids, J. Liebigs Ann Chem, pp. 241- (1966).
Seo, Jeong Kon et al., A Peptide wih Unique Receptor Specificity, Jimmunol, pp. 1895-1901 (1997).
Vanderah, T.W. et al., Mediation of Swim-Stress Antinociception by the Opioid Delta2Receptor in the Mouse1, J. Pharm. Exper. Therapeutics, vol. 262:1 (1992).
Vogler, von K. et al., Synthese von All-D-Val5-Angiotensin II-Asp1-β-Amind1), Helv Chim Acta, 48:6:152, pp. 1407-1414 (1965).
Vonvoigtlander, P.F. et al., U-50,488: A Selective and Structurally Novel Non-Mu (Kappa) Opioid Agonist, J. Pharm. Exper. Therapeutics, 224:7-12 (1983).
Wang, X. et al., Application of topologically segregated bilayer beads in ‘one-bead one-compound’ combinatorial libraries, J. Peptide Res. 65, pp. 130-138 (2005).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, J. Peptide Sci., 6 supp:S189 (2000) (Abstract).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, Posters:1 Bioactive, P358 (Poster).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, Peptides 2000:Proc. Of 36thEur Peptide Symp. (J. Martinez & J.A. Fehrentz, eds.) Editions EDK, pp. 775-776 (2001) (Mini-publication).
Alexander Roberta Vezza
Chalmers Derek T.
Jiang Guangcheng
Luo Zhiyong
Menzaghi Frederique
Bradley Christina Marchetti
Cara Therapeutics, Inc.
Pillsbury Winthrop Shaw & Pittman LLP
Tsang Cecilia
LandOfFree
Synthetic peptide amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic peptide amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptide amides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2761170